ScholarIQanswers from OpenAlex
University Hospitals of the Ruhr-University of Bochum
InstitutionResearch output, impact & collaborations
University Hospitals of the Ruhr-University of Bochum is a research organisation in Bochum, DE. OpenAlex records 6,449 works and 312,048 citations for it. 1,482 researchers list it as their most recent affiliation.
6,449
Works
312,048
Citations
1,482
Researchers
67.3
Avg h-index
How has University Hospitals of the Ruhr-University of Bochum's publication output changed over time?
ScholarIQpublication output · 2004–2019
Output grew200% over the shown period — from 1 works in 2004 to 3 in 2019.
20042009201020112015201620182019
Who are the most-cited researchers behind University Hospitals of the Ruhr-University of Bochum?
ScholarIQtop researchers by citations
What are the most-cited papers on University Hospitals of the Ruhr-University of Bochum?
ScholarIQmost cited works
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen, Diana Miao, Bastian Schilling, Sachet A. Shukla, Christian U. Blank, Lisa Zimmer, Antje Sucker, Uwe Hillen, Marnix H. Geukes Foppen, Simone M. Goldinger, Jochen Utikal, Jessica C. Hassel, Benjamin Weide, Katharina C. Kaehler, Carmen Loquai, Peter Mohr, Ralf Gutzmer, Reinhard Dummer, Stacey Gabriel, Catherine J. Wu, Dirk Schadendorf, Levi A. Garraway
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E. Schmidt, Eduard Montanya, Jason Brett, Marcin Zychma, Lawrence Blonde
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu, Bastian Schilling, Derek Liu, Antje Sucker, Elisabeth Livingstone, Livnat Jerby‐Arnon, Lisa Zimmer, Ralf Gutzmer, Imke Satzger, Carmen Loquai, Stephan Grabbe, Natalie I. Vokes, Claire A. Margolis, Jake R. Conway, Meng Xiao He, Haitham Elmarakeby, Felix Dietlein, Diana Miao, Adam Tracy, Helen Gogas, Simone M. Goldinger, Jochen Utikal, Christian U. Blank, Ricarda Rauschenberg, Dagmar von Bubnoff, Angela M. Krackhardt, Benjamin Weide, Sebastian Haferkamp, Felix Kiecker, Ben Izar, Levi A. Garraway, Aviv Regev, Keith T. Flaherty, Annette Paschen, Eliezer M. Van Allen, Dirk Schadendorf
How much of the research on University Hospitals of the Ruhr-University of Bochum is open access?
ScholarIQopen access share
75%OPEN ACCESS